Clinical Trial Update: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating palbociclib for HR-positive, HER2-negative isolated locoregional recurrence of breast cancer. The study is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Breast Cancer Recurrent | Phase 3 | Status: ACTIVE_NOT_RECRUITING